^
3d
On-demand reprogramming of immunosuppressive microenvironment in tumor tissue via multi-regulation of carcinogenic microRNAs and RNAs dependent photothermal-immunotherapy using engineered gold nanoparticles for malignant tumor treatment. (PubMed, Biomaterials)
The SNAs@CCMR consisted of antisense oligonucleotides grafted gold nanoparticles (SNAs) as core and TLR7 agonist imiquimod (R837) functionalized cancer cell membrane (CCM) as shell, in which the acid-labile Schiff base bond was used to connect the R837 and CCM...These chain processes not only damaged the primary tumor, but also produced plenty of tumor-associated antigens, which matured the surrounding dendritic cells (DCs) and activated anti-tumor T cells along with the released R837, resulting in the enhanced immunotherapy with suppressive immune escape. Both in vivo and in vitro experiments demonstrated that our nanoparticles were able to inhibit primary tumor and its metastasis via multi-regulation of carcinogenic microRNAs and RNAs dependent photothermal-immune activations, which provided a promising strategy to reprogram the immunosuppressive microenvironment in tumor tissue for better malignant tumor therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MIR21 (MicroRNA 21) • MIR130A (MicroRNA 130a)
|
PD-L1 expression
|
Zyclara (imiquimod)
6d
Knockdown of GBP5 alleviates renal damage caused by psoriasis by regulating NF-κB/STAT3 pathway. (PubMed, Allergol Immunopathol (Madr))
Inhibiting GBP5 can mitigate the renal injury caused by psoriasis through NF-κB/STAT3 axix.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • GBP5 (Guanylate Binding Protein 5)
|
GBP5 expression
|
Zyclara (imiquimod)
6d
Gypenosides alleviates HaCaT keratinocyte hyperproliferation and ameliorates imiquimod-induced psoriasis in mice. (PubMed, Allergol Immunopathol (Madr))
In summary, Gyp reduced excessive cell growth and inflammation in psoriasis by suppressing nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) through activation of Nrf2.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL1B (Interleukin 1, beta) • IL22 (Interleukin 22)
|
IL6 expression
|
Zyclara (imiquimod)
9d
New P2 trial
|
metformin • Zyclara (imiquimod)
9d
Topical Aldara (Imiquimod) for Oral Cancer (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Medical University of South Carolina | Trial completion date: Sep 2024 --> Dec 2024
Trial completion date
|
Zyclara (imiquimod)
15d
Comparing Immune Responses to Topical Imiquimod (clinicaltrials.gov)
P=N/A, N=6, Terminated, University of California, Davis | N=110 --> 6 | Active, not recruiting --> Terminated; PI failed to submit the study for continuing review to IRB, failed to respond.
Enrollment change • Trial termination
|
TLR7 (Toll Like Receptor 7)
|
Zyclara (imiquimod)
18d
Shikonin promotes ferroptosis in HaCaT cells through Nrf2 and alleviates imiquimod-induced psoriasis in mice. (PubMed, Chem Biol Interact)
Nrf2 and GPX4 might be the two major targets of SHK in psoriatic skin lesion. Our study highly lighted the basic biological mechanism of SHK on ferroptosis regulation.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • NCOA4 (Nuclear Receptor Coactivator 4) • HMOX1 (Heme Oxygenase 1) • GPX4 (Glutathione Peroxidase 4) • IL17A (Interleukin 17A)
|
GPX4 expression • HMOX1 expression
|
Zyclara (imiquimod)
19d
Delivery of imiquimod to intestinal lymph nodes following oral administration. (PubMed, Int J Pharm)
This work suggests that the highly lipophilic prodrug approach can efficiently deliver IMQ to intestinal lymphatics. In addition, this study demonstrates the feasibility of an amide prodrug approach for intestinal lymphatic targeting.
Journal
|
TLR7 (Toll Like Receptor 7)
|
Zyclara (imiquimod)
23d
Use of modified human hemangioma tissue cultures and human umbilical vein endothelial cell cultures to gain mechanistic insights into imiquimod treatment for infantile hemangioma. (PubMed, In Vitro Cell Dev Biol Anim)
Oral propranolol is a mainstay of treatment for IH and is well-tolerated, though propranolol-refractory IH and other drug-related adverse events are documented and can limit its usage. From this preliminary analysis, we discerned that hemangioma tissues can be grown in tissue culture and used for drug treatment studies. We also conclude acute and chronic modulation of cell cycle, angiogenesis factors, and immunostimulatory conditions may be associated with imiquimod mechanisms of action in hemangioma involution.
Preclinical • Journal
|
CCND1 (Cyclin D1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IFNA1 (Interferon Alpha 1)
|
Zyclara (imiquimod)
25d
BML-111 Modulates and Alleviates p38/MAPK Signaling Pathway and Th1/Th2/Th17 Cytokine Response in Murine Psoriasis-Like Dermatitis. (PubMed, Discov Med)
BML-111 modulates the p38/MAPK signaling pathway and Th1/Th2/Th17 cytokine response, and alleviates psoriasis-like dermatitis in mice.
Preclinical • Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
|
IL4 elevation
|
Zyclara (imiquimod)
27d
Chronic stress-mediated dysregulations in inflammatory, immune and oxidative circuitry impairs the therapeutic response of methotrexate in experimental autoimmune disease models. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Here, in this study, we investigated the detrimental impact of an 8-week chronic unpredictable stress (CUS) protocol on the progression of arthritis and psoriasis using collagen-induced arthritis (CIA) and imiquimod (IMQ)-induced psoriasis rat models, respectively. Moreover, the therapeutic efficacy of MTX was notably reduced in stressed rats compared to non-stressed, underscoring the detrimental effects of chronic stress on treatment outcomes. Taken together, our results emphasize the importance of considering chronic stress as a critical factor in the management of autoimmune diseases.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
|
methotrexate • Zyclara (imiquimod)
1m
Xiaoyin-anshen formula alleviates psoriasis complicated by sleep disturbances by regulating melatonin, antioxidant enzymes, and pro-inflammatory cytokines in mice. (PubMed, Front Pharmacol)
A mouse model for psoriasis combined with SDs was established by smearing 62.5 mg of 5% imiquimod (IMQ) cream for seven consecutive days, along with a daily injection of p-chlorophenyl alanine (PCPA) solution at a dosage of 300 mg/kg at days 6-7...XYAS may treat psoriasis complicated by SDs through two main mechanisms: (1) Improving melatonin-RORα axis in the skin can lead to an increase in mnSOD and a reduction in Cyt-C levels, which provide protection against oxidative stress, mitochondrial damage, and psoriatic inflammation. (2) Reducing IL-6, IL-17A, and TNF-α production to suppress IL-23/Th17 pro-inflammatory signaling axis and epidermal hyperplasia in psoriasis.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • SOD2 (Superoxide Dismutase 2)
|
Zyclara (imiquimod)
1m
Immunotherapy in Basal Cell Carcinoma. (PubMed, J Clin Med)
Local therapies can be considered in superficial and low-risk nodular BCCs, with imiquimod frequently used for its antitumor and immunoregulatory properties...Interferons and Interleukin-2 were evaluated in a small number of studies with different results. Systemic immunotherapies with programmed death-ligand 1 (PD-L1) inhibitors showed inconsistent results in patients with advanced BCCs, being effective in some patients that progressed on or were intolerant to hedgehog pathway inhibitors (HHI).
Review • Journal
|
IL2 (Interleukin 2)
|
Zyclara (imiquimod)
1m
Ginseng fruit rare saponins (GFRS) improved inflammatory response: In vitro and in vivo assessment. (PubMed, Fitoterapia)
In the imiquimod (IMQ) -induced mouse inflammatory model, the therapeutic effect of GFRS on the pathogenesis of psoriasis-like dermatitis was studied...GFRS restored IMQ-induced spleen size and reduced the secretion and expression of TNF-α, IL-6, Interferon-γ (IFN-γ) and IL-17 A in serum. In summary, our results demonstrate that GFRS alleviates IMQ-induced dermatitis symptoms, effectively reduces the secretion of inflammatory factors, and inhibits IL-17 A expression.
Preclinical • Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
|
IL6 expression
|
Zyclara (imiquimod)
1m
Invasive acantholytic anaplastic extramammary Paget disease: A previously unreported neoplasm in the vulva and review of the literature. (PubMed, Gynecol Oncol Rep)
An 87-year-old female presented with a recurrent vulvar lesion refractory to topical imiquimod and treated with multiple wide local excisions (WLE)...AAEMPD, a rare variant of EMPD, shares similar prognosis and behavior with the classic Paget disease. Recognition and accurate diagnosis of this subtype is crucial for optimal patient management, given distinct treatment strategies compared with other entities in the differential diagnosis.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • KRT7 (Keratin-7) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
|
Zyclara (imiquimod)
2ms
The molecular mechanism of berberine affecting psoriasis skin inflammation by regulating keratinocyte pyroptosis via the p38 MAPK/NF-κB pathway. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
A psoriasis-like skin inflammation mouse model was induced by imiquimod (IMQ) and treated with BBR and a p38 activator anisomycin...BBR repressed NLRP3 inflammasome activation and pyroptosis by inhibiting the p38 MAPK/NF-κB pathway. Collectively, BBR suppressed keratinocyte NLRP3/GSDMD pathway pyroptosis by suppressing the p38 MAPK/NF-κB pathway, thereby affecting psoriasis skin inflammation.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
Zyclara (imiquimod)
2ms
The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity. (PubMed, JCI Insight)
We found elevated levels of mitochondrial DNA in patients with psoriasis, along with high expression of AIM2 in both the human psoriatic epidermis and a mouse model of psoriasis induced by topical imiquimod (IMQ) application. Finally, the genetic absence of inflammasome components downstream AIM2, ASC, and caspase-1 alleviated IMQ-induced skin inflammation. Collectively, our data show that AIM2 is involved in developing psoriasis through its canonical activation.
Journal
|
AIM2 (Absent In Melanoma 2) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CASP1 (Caspase 1)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
2ms
Imiquimod inhibits U87 cell proliferation and migration in vitro through inhibition of STAT-3/NF-κB signalling pathway. (PubMed, Pak J Pharm Sci)
Adding a STAT-3 inhibitor yielded similar effects to IMQ, altering cell proliferation, migration and apoptosis. Overall, IMQ appears to inhibit U87 cell proliferation and migration, inducing programmed cell death through STAT-3 modulation.
Preclinical • Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
Zyclara (imiquimod)
2ms
Upregulated SKP2 Empowers Epidermal Proliferation Through Downregulation of P27 Kip1. (PubMed, Ann Dermatol)
Our results suggest that elevated SKP2 can empower keratinocytes proliferation and psoriasis-like epidermis hyperplasia via downregulation of P27 Kip1. Therefore, targeting SKP2-P27 Kip1 axis might be a promising therapeutic strategy for the treatment of psoriasis in future.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • SKP2 (S-phase kinase-associated protein 2)
|
Zyclara (imiquimod)
2ms
Imiquimod and Pembrolizumab in Treating Patients with Stage IIIB-IV Melanoma (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2024 --> Dec 2025
Trial completion date • Metastases
|
Keytruda (pembrolizumab) • Zyclara (imiquimod)
2ms
The Protective Effects of Mcl-1 on Mitochondrial Damage and Oxidative Stress in Imiquimod-Induced Cancer Cell Death. (PubMed, Cancers (Basel))
Mcl-1 overexpression ameliorates IMQ-induced ROS generation and mitochondrial fragmentation, thereby increasing mitochondrial stability and ultimately attenuating IMQ-induced cell death. Investigating the roles of Mcl-1 in mitochondria is a potential strategy for cancer therapy development.
Journal • IO biomarker
|
MCL1 (Myeloid cell leukemia 1) • IL6 (Interleukin 6) • TLR7 (Toll Like Receptor 7)
|
MCL1 overexpression • MCL1 expression
|
Zyclara (imiquimod)
2ms
A nanodrug provokes antitumor immune responses via synchronous multicellular regulation for enhanced cancer immunotherapy. (PubMed, J Colloid Interface Sci)
In addition, an immune adjuvant of imiquimod (R837) is incorporated...Specifically, QUE inhibits the activation state of hepatic stellate cells and reduces highly expressed programmed death receptor ligand 1 (PD-L1) on tumor cells, meanwhile R837 exposes calreticulin on tumor cell surface as an "eat me" signal and leads to a large number of DCs maturing for enhanced antigen presentation. Consequently, the cooperative immune regulation results in a remodeled TME with high infiltration of cytotoxic T lymphocytes for enhanced HCC immunotherapy, which demonstrates an effective immunotherapy paradigm for dense ECM characterized solid tumors with high PD-L1 expression.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CALR (Calreticulin)
|
PD-L1 expression • PD-L1 overexpression
|
Zyclara (imiquimod)
3ms
TLR7-Induced Mitochondrial Reactive Oxygen Species Production in Monocyte-derived Dendritic Cells Drives IL-12-Dependent NK Cell Activation and Enhances Antitumor Immunity. (PubMed, J Immunol)
We showed that TLR7 activation by imiquimod in peripheral blood monocyte-derived CD11c+ DCs triggered mROS production, leading to enhanced IL-12 secretion and subsequent NK cell activation, as evidenced by increased IFN-γ production and tumor cell cytotoxicity. Notably, mROS neutralization abrogates NK cell-mediated tumor cell lysis, and TLR7-mediated DC activation of NK cells occurs independently of MyD88, suggesting involvement of the noncanonical NF-κB pathway. Our findings provide a rationale for targeting the TLR7/mROS/IL-12 axis to enhance the efficacy of DC-based cancer immunotherapy.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IFNG (Interferon, gamma) • ITGAX (Integrin Subunit Alpha X) • TLR7 (Toll Like Receptor 7)
|
Zyclara (imiquimod)
3ms
Choline-based ionic liquids enhance the dermal delivery of cyclosporine a for potential treatment of psoriasis. (PubMed, Drug Deliv Transl Res)
Moreover, CyA-loaded ILs (0.5%, w/w) significantly relieved the symptoms of psoriasis in an imiquimod (IMQ)-induced mouse model, and the levels of inflammatory factors, including tumor necrosis factor α, interleukin 22 and interleukin 17, in the affected area were reduced by 71.7%, 75.6%, and 89.3%, respectively. After 7 days of consecutive application, [Ch][So] did not cause significant irritation. In conclusion, ILs demonstrate promising potential for the dermal delivery of CyA for the treatment of psoriasis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL22 (Interleukin 22)
|
Zyclara (imiquimod) • cyclosporin A microemulsion
3ms
A new TGF-β risk score predicts clinical and immune landscape in colorectal cancer patients. (PubMed, Ann Gastroenterol Surg)
The feature gene TGFB2 could inhibit the efficacy of drugs such as XAV-939, Staurosporine, and Dasatinib, but promote the efficacy of drugs such as CUDC-305 and by-product of CUDC-305. Similarly, RBL1 could inhibit the drug action of Fluphenazine and Imiquimod but promote that of Irofulven. A CRC risk prognostic signature was developed on basis of TGF-β-related genes, which provides a reference for risk and further therapeutic selection of CRC patients.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • TGFB1 (Transforming Growth Factor Beta 1) • RBL1 (RB Transcriptional Corepressor Like 1) • TGFB2 (Transforming Growth Factor Beta 2)
|
dasatinib • Zyclara (imiquimod) • XAV-939 • fluphenazine • RGRN-305 • irofulven-1 (LP-100)
3ms
Gold Nano Frameworks with Mesopores for Synergistic Immune-Thermal Therapy in Hepatic Carcinoma: A Paradigm Shift in Immune Checkpoint Blockade. (PubMed, ACS Appl Mater Interfaces)
Assisted by imiquimod, substantial CTL infiltration occurs, accompanied by pro-inflammatory factor release (TNF-α, IL-6), transforming M2 macrophages into the M1 phenotype. Ultimately, the proposed strategy combines PD-L1/PD-1 blockade, imiquimod and mild thermal treatment to synergistically enhance tumor immunogenicity, remodel the TME, and restrain hepatic carcinoma, making strides in ICB synergistic immune-thermal therapy.
Journal • Checkpoint inhibition • Checkpoint block
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
Zyclara (imiquimod)
3ms
Topical application of phenformin ameliorates the psoriasis-like inflammatory response via the inhibition of c-Myc expression in keratinocytes. (PubMed, Biochem Biophys Res Commun)
phenformin ameliorates the psoriasis-like inflammatory response by inhibiting c-Myc expression in keratinocytes, suggesting its potential as a topical drug for the treatment of psoriasis.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
|
JQ-1 • metformin • Zyclara (imiquimod)
4ms
Enhanced targeted liposomal delivery of imiquimod via aptamer functionalization for head and neck cancer therapy. (PubMed, Colloids Surf B Biointerfaces)
Additionally, they decreased the migration (from ∼24 % to ∼8 %; p < 0.0001) and invasion (to 11 %; p = 0.0047) capacities of the cancer cells. In summary, the produced liposomes represent a promising approach to enhance the anticancer potential of IQ in head and neck cancer, particularly in tongue cancer.
Journal
|
NCL (Nucleolin)
|
Zyclara (imiquimod)
4ms
Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model. (PubMed, Int J Mol Sci)
Imiqualines are analogues of the immunomodulatory drug imiquimod...In summary, we showed that EAPB02303 potently reduced the activity of IIS and Ras-MAPK signaling in C. elegans. Our results revealed the mechanism of action of EAPB02303 against human cancers associated with hyperactivated IIS pathway and oncogenic Ras mutations.
Journal
|
IGF1 (Insulin-like growth factor 1)
|
Zyclara (imiquimod)
4ms
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024
Trial completion date • Metastases
|
Keytruda (pembrolizumab) • Zyclara (imiquimod)
4ms
Photothermal therapy improves the efficacy of topical immunotherapy against melanoma. (PubMed, Photodiagnosis Photodyn Ther)
The study showed that LIT inhibited the growth of both primary and abscopal melanoma by activating systemic antitumor immune responses and reversing the immunosuppressive tumor microenvironment, making LIT a potential method for advanced melanoma treatment.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Zyclara (imiquimod)
4ms
Fe3O4@R837 Nanoplatform Enhances Chemical Dynamic Therapy and Immunotherapy: Integrated Transcriptomic Analysis Reveals Key Genes in Breast Cancer Prognosis. (PubMed, ACS Biomater Sci Eng)
Additionally, cancer immunotherapy using immune drugs, such as imiquimod (R837), has shown promise in activating T cells to kill tumor cells...Our results indicate that these six key genes regulate immune cell recruitment to increase T-cell cytotoxicity and kill tumors. Targeting these key genes can enhance immunotherapy and improve the breast cancer prognosis.
Journal • IO biomarker
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD27 (CD27 Molecule) • GZMK (Granzyme K) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
|
Zyclara (imiquimod)
4ms
Shifting phenotype and differentiation of CD11b+Gr.1+ immature heterogeneous myeloid derived adjuster cells support inflammation and induce regulators of IL17A in imiquimod induced psoriasis. (PubMed, Inflamm Res)
Our results indicate that altered MDAC properties in psoriatic condition sustains pathological inflammation and RORγt and NFAT1 as promising intervention target for psoriasis management.
Journal
|
ITGAM (Integrin, alpha M) • IL17A (Interleukin 17A)
|
Zyclara (imiquimod)
4ms
CaCO3-Encapsulated polydopamine with an adsorbed TLR7 agonist for improved tumor photothermal immunotherapy. (PubMed, Heliyon)
Toll-like receptor 7 (TLR7) agonist imiquimod (IMQ) and bispecific antibody (BsAb) blinatumomab were loaded onto PDA-CaCO3 nanoparticles (NPs). PICB had a strong inhibitory effect on tumor growth in 4T1 tumor-bearing mice, and has no toxicity to other organs. Therefore, the multifunctional drug delivery nanosystem constructed in this study could effectively exert the properties of various components in vivo, fully demonstrate the synergistic effect between immunotherapy and photothermal therapy, thus significantly improving the tumor therapeutic efficacy, and has a promising clinical application.
Journal
|
CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
Blincyto (blinatumomab) • Zyclara (imiquimod)
4ms
The effect of dapagliflozin ointment on induced psoriasis in an experimental model. (PubMed, J Med Life)
Dapagliflozin ointment significantly reduced these cytokine levels and disease scores, indicating anti-psoriatic and anti-inflammatory properties. Therefore, when applied topically, dapagliflozin ointment had strong efficacy against imiquimod-induced psoriatic skin inflammation, suggesting its potential as a novel therapeutic option for psoriasis treatment.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL17A (Interleukin 17A)
|
Zyclara (imiquimod) • Farxiga (dapagliflozin)
4ms
Artemisia monosperma essential oil nanoformulations alleviate imiquimod-induced psoriasis-like dermatitis in mice. (PubMed, Int Immunopharmacol)
Despite the healing properties of BF, NE showed a more prominent effect on treating the psoriatic model, which could be referred to as its high skin penetration ability and absorption. These results potentially contribute to documenting experimental and theoretical evidence for the clinical uses of A.monosperma EO nanoformulations for treating psoriasis.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
|
Zyclara (imiquimod)
4ms
Biochanin A Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice by Modulating the NF-κB and MAPK Signaling Pathways. (PubMed, Inflammation)
Furthermore, our findings demonstrated that BCA treatment alleviated the psoriasis-like symptoms via modulating NF-κB and MAPK signaling pathways. Our results demonstrate the therapeutic potential of BCA against IMQ-induced psoriasis-like skin inflammation.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • MMP9 (Matrix metallopeptidase 9) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
Zyclara (imiquimod)
4ms
Recurrence of Quadruple Extramammary Paget's Disease after 12 Years: A Case Report and Literature Review. (PubMed, Case Rep Dermatol)
It has been reported that the therapeutic effects of imiquimod can be expected in in situ EMPD. Therefore, quadruple EMPD may be a good indication of treatment option. EMPD is a disease whose pathogenesis is not yet clear; however, it is hoped that the origin and aetiology of EMPD will be elucidated from the clinical features of multiple EMPD in the future.
Review • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
Zyclara (imiquimod)
4ms
Acquired epidermodysplasia verruciformis syndrome in HIV-infected patients: a systematic review. (PubMed, Arch Dermatol Res)
Most treatments have low efficacy, the most described are glycolic acid 15%, 5-fluorouracil 5%, imiquimod 5%, and topical retinoids all of them in monotherapy or combined with cryotherapy. Other alternatives include topical cidofovir and systemic retinoids with variable results...This review opens new opportunities for future research. Additionally, we provide clear and useful key points for the practice of dermatologists and all professionals treating HIV patients around the world.
Review • Journal
|
CD4 (CD4 Molecule)
|
5-fluorouracil • Zyclara (imiquimod)
4ms
TLR Agonists Modify NK Cell Activation and Increase Its Cytotoxicity in Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
We stimulated NK cells from the peripheral blood mononuclear cells from children with acute lymphoblastic leukemia and NK cells isolated, and the NK cells were stimulated with specific TLR ligands (Poly I:C, Imiquimod, R848, and ODN2006) and we evaluated changes in IFN-γ, CD107a, NKG2D, NKp44 expression, Granzyme B secretion, cytokine/chemokine release, and cytotoxic activity...Importantly, R848 and ODN 2006 significantly improved cytotoxicity against leukemic cells. Overall, TLR stimulation enhances NK cell activation, suggesting TLR8 (R848) and TLR9 (ODN 2006) ligands as promising candidates for antitumor immunotherapy.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • LAMP1 (Lysosomal Associated Membrane Protein 1) • TLR9 (Toll Like Receptor 9) • GZMB (Granzyme B) • TLR8 (Toll Like Receptor 8) • NKG2D (killer cell lectin like receptor K1)
|
Zyclara (imiquimod)
5ms
Topical application of a BCL-2 inhibitor ameliorates imiquimod-induced psoriasiform dermatitis by eliminating senescent cells. (PubMed, J Dermatol Sci)
We revealed the roles of senescent CD4+ T cells in developing psoriasis and highlighted the therapeutic potential of topical ABT-737 gel in treating psoriasis through the elimination of senescent cells, modulation of the TCR αβ repertoire, and regulation of the TET2-Th17 cell pathway.
Journal • IO biomarker
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD4 (CD4 Molecule) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
Zyclara (imiquimod) • ABT-737
5ms
Inhibitory Effect of Evodiamine on Psoriasis Lesions and Itching in Mice. (PubMed, Clin Cosmet Investig Dermatol)
Evodiamine reduced pruritus and inhibited inflammation by decreasing the levels of inflammatory mediators TNF-α, IL-23, and IL-17A in the serum of Imiquimod-induced mice and attenuated the mRNA and protein expression levels of SP, NGF, CGRP, TRPV1, TRPV3, and TRPV4 in the skin. Evodiamine is an effective treatment for psoriasis and pruritus, due to its ability to inhibit immune inflammation and pruritic mediators.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1)
|
Zyclara (imiquimod)